| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/05/2023 | 359.77% | Stephens & Co. | → $12 | Reiterates | Overweight → Overweight |
| 03/28/2023 | 359.77% | Stephens & Co. | → $12 | Reiterates | → Overweight |
| 08/15/2022 | 321.46% | BTIG | $10 → $11 | Maintains | Buy |
| 08/24/2021 | 627.97% | Stephens & Co. | → $19 | Initiates Coverage On | → Overweight |
| 08/24/2021 | — | William Blair | Initiates Coverage On | → Outperform | |
| 08/24/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 08/24/2021 | 589.66% | Stifel | → $18 | Initiates Coverage On | → Buy |
| 08/24/2021 | 742.91% | BTIG | → $22 | Initiates Coverage On | → Buy |
What is the target price for MaxCyte (MXCT)?
The latest price target for MaxCyte (NASDAQ: MXCT) was reported by Stephens & Co. on October 5, 2023. The analyst firm set a price target for $12.00 expecting MXCT to rise to within 12 months (a possible 359.77% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for MaxCyte (MXCT)?
The latest analyst rating for MaxCyte (NASDAQ: MXCT) was provided by Stephens & Co., and MaxCyte reiterated their overweight rating.
When is the next analyst rating going to be posted or updated for MaxCyte (MXCT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of MaxCyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for MaxCyte was filed on October 5, 2023 so you should expect the next rating to be made available sometime around October 5, 2024.
Is the Analyst Rating MaxCyte (MXCT) correct?
While ratings are subjective and will change, the latest MaxCyte (MXCT) rating was a reiterated with a price target of $0.00 to $12.00. The current price MaxCyte (MXCT) is trading at is $2.61, which is within the analyst's predicted range.